Introduction L’International Myositis Assessment and Clinical Studies Group a formulé des recommandations précieuses pour l’orientation des cliniciens et la sécurité des patients, en classant et hiérarchisant le risque potentiel de cancer induit selon les sous-types de myopathies, et leurs manifestations cliniques.Toutefois, ces recommandations pourraient ne pas être strictement applicables à tous les patients, en raison (1) de la prévalence variable des sous-types de MI selon les groupes ethniques et (2) du fait du manque de données sur les cancers liés aux MI chez les non-Caucasiens.L’objectif de notre étude était d’évaluer le risque de cancer au cours des MI en Martinique, et d’identifier de potentiels facteurs de risque dans notre population d’ascendance majoritairement africaine. Patients et méthodes Nous avons mené une étude longitudinale rétrospective dans le seul centre tertiaire de l’île de la Martinique et inclus les patients atteints de myopathies inflammatoires vus entre le 1er janvier 2000 et le 30 juin 2023. Les patients atteints de MI ont été appariés avec le registre martiniquais des cancers. Les taux d’incidence standardisés au niveau mondial (SIR) ont été calculés pour les comparaisons d’incidence avec la population générale de la Martinique. Résultats Le dernier rapport du registre du cancer de la Martinique révèle un SIR mondial de 301,6 pour les hommes et de 168,4 pour 100 000 années-personnes pour les femmes. Comparativement, le SIR du cancer dans le groupe IIM était de 89,3 [IC95 % : 22,7–155,9] et 114,6 [IC95 % : 17,3–211,9] pour 100 000 personnes-années pour les hommes et les femmes, respectivement.Douze cancers sur 18 (67 %) ont été diagnostiqués 36 mois avant ou après le début de l’IIM (délai médian de 2,3 mois [IQR : −13,5 à 20,4]) et caractérisés comme liés à la MI. La dermatomyosite et le syndrome des antisynthétases étaient les sous-types de MI les plus représentés (50 % [p=0,07] et 42 % [p=0,5], respectivement).Au diagnostic de la MI, une pneumopathie interstitielle diffuse (PID) a été détectée chez 17 patients, dont 11 (65 %) avaient un syndrome antisynthétase (ASyS), 3 (18 %) une myosite de chevauchement et 2 (12 %) une dermatomyosite. La PID était plus fréquente chez les patients avec (56 %) que chez ceux sans (9 %) cancers liés à la MI, avec un rapport de risque de 12,1 (IC95 % : 3,23–45, p<0,001). Conclusion L’incidence des cancers au cours des MI semble réduite chez les hommes et les femmes en Martinique. La faible prévalence du tabagisme en Martinique est une explication possible parmi d’autres, mais l’impact de l’ethnie ne peut être exclu.Bien que la puissance statistique limite certaines conclusions concernant des facteurs de risque retenus par l’International Myositis Assessment and Clinical Studies Group, la PID est identifiée comme un facteur de risque élevé pour le développement d’un cancer lié à la MI dans notre population, en net contraste avec les recommandations actuelles.Par conséquent, dans l’attente d’autres études plus importantes, nous préconisons une attention particulière et un dépistage renforcé du cancer chez les patients d’origine africaine atteints de MI compliquée de PID.

Background: Martinique is the second French Region with the lowest physician-to-population ratio, which may affect waiting times for access to care.Objectives: To assess (i) factors influencing waiting times from diagnosis to cancer-related treatments in breast cancer women in Martinique, and (ii) the impact of waiting times on patients' survival.Study design: Retrospective observational study.Methods: Data on women diagnosed with invasive breast cancer between 1st January 2013 and 31st December 2017 and initially treated by surgery were extracted from the Martinique population-based registry. A cox model was performed to find predictive factors for waiting times. A log-rank test was used to compare time-to-treatment between groups.Results: In total, 713 patients were included (mean age: 58 +/- 13). Median time from diagnosis to surgery was 40 [25-60] days. Age at diagnosis was found to predict variations in waiting times. Patients > 75 had longer waiting time to surgery than those < 40 or [40-50] (P = 0.016 and P < 0.001, respectively). Women with a time-to-treatment >= 4 months had a significant lower survival (P < 0.01).Conclusions: Specific interventions are needed to improve waiting time from diagnosis to initial treatment, as they are longer than recommended and affect survival time.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4. 0/).

Background Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. Methods We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. Results The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. Conclusions To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.

INTRODUCTION Global variations in survival for brain tumours are very wide when all histological types are considered together. Appraisal of international differences should be informed by the distribution of histology, but little is known beyond Europe and North America. PATIENTS AND METHODS The source for the analysis was the CONCORD data base, a programme of global surveillance of cancer survival trends, which includes the tumour records of individual patients from more than 300 population-based cancer registries. We considered all patients aged 0-99 years who were diagnosed with a primary brain tumour during 2000-2014, whether malignant or non-malignant. We presented the histology distribution of these tumours, for patients diagnosed during 2000-2004, 2005-2009, and 2010-2014. RESULTS Records were submitted from 60 countries on five continents, 67,331 for children and 671,085 for adults. After exclusion of irrelevant morphology codes, the final study population comprised 60,783 children and 602,112 adults. Only 59 of 60 countries covered in CONCORD-3 were included, because none of the Mexican records were eligible. We defined 12 histology groups for children, and 11 histology groups for adults. In children (0-14 years), the proportion of low-grade astrocytomas ranged between 6% and 50%. Medulloblastoma was the most common sub-type in countries where low-grade astrocytoma was less commonly reported. In adults (15-99 years), the proportion of glioblastomas varied between 9% and 69%. International comparisons were made difficult by wide differences in the proportion of tumours with unspecified histology, which accounted for up to 52% of diagnoses in children and up to 65% in adults. CONCLUSIONS To our knowledge, this is the first account of the global histology distribution of brain tumours, in children and adults. Our findings provide insights into the practices and the quality of cancer registration worldwide.

Background. - We aimed to describe incidence and mortality from colorectal cancer, and temporal trends between 1982 and 2011 in Martinique (French West-Indies).Methods. - This was a descriptive, longitudinal, observational study based on data from the Martinique cancer registry. The study included all incident cases of colorectal cancer between 1982 and 2011. We recorded sociodemographic data and clinical variables (histology, site according to the WHO classification). Cancer cases were recorded in strict conformity with the international standards. Annual rate of change was calculated, direct standardisation was used for incidence and mortality age standardised rates (ASR). The comparative incidence figure and comparative mortality figure (95% confidence intervals) were calculated.Results. - In total, 2530 patients were included in our study; 1243 died. In the period 2007-2011, a considerable increase in incidence was observed, making colorectal cancer the second leading cause of cancer deaths in both sexes (8.9% and 10.5%). In men, ASR for incidence increased from 9.6/100,000 person-years in the period 1982-1986 to 27.2/100,000 person-years in the period 2007-2011, with a notable acceleration of the increase. In women, ASR increased from 8.4 to 19.8/100,000 person-years over the same periods. For the latest period 2007-2011, mortality rates were 9.9 and 7.6/100,000 person-years for men and for women respectively. Regardless of the sex, there was a strong increase in the incidence of right colon cancer, which became the most common colorectal site in women in Martinique.Conclusion. - Our findings confirm the increase in the incidence of colorectal cancer that started in the 2000s. Trends observed reflect a salient epidemiological transition of the Caribbean. (C) 2017 Elsevier Masson SAS. All rights reserved.

BACKGROUND:The Caribbean ranks seventh among world regions most affected by cervical cancer. Social health inequalities, such as differences in access to screening services, engender disparities in incidence and mortality between low- and middle-income countries and industrialized countries. The French National Cancer Plan 2014-2019 focuses on reducing inequalities in cervical cancer.OBJECTIVE:The aim of this study was to describe the geographical distribution and overall survival of cervical cancer, based on data from a population-based cancer registry in Martinique (French West-Indies).METHODS:We included all cases of cervical cancer diagnosed between 2002 and 2011. The geographical distribution was described by zone of residence and by aggregated units for statistical information (IRIS). Based on the results of the model, standardized incidence rates (SIRs) were calculated using a Gamma Poisson model. Survival rates were calculated using the Kaplan-Meier method. Cox proportional hazards models were used to investigate the risk factors for cervical cancer mortality.RESULTS:A total of 1253 cases were analyzed (947 in situ tumors and 306 invasive cancers). 1230 cases with geolocalization were used to map the distribution of the incidence of in situ and invasive cervical cancers. Five IRIS were significantly over-incident. The 5-year overall survival rate was 55%, with a median survival of 6.5 years [95% CI: 4.9-10.1]. Multivariate analysis confirmed age at diagnosis (HR = 2.15 [1.50-3.09]; p < 0.0001), FIGO stage (HR = 3.53 [2.50-4.99]; p < 0.0001) and zone of residence (HR = 1.51 [1.06-2.13]; p = 0.02) as risk factors.CONCLUSIONS:Prognostic factors suggest that cervical cancer needs to be diagnosed at an early stage. Our results could allow cervical cancer screening programs to clearly identify geographical areas that would benefit from targeted interventions with a view to reducing incidence and mortality of cervical cancer in the Caribbean.

The majority of monoclonal gammopathy of undetermined significance (MGUS) are benign forms that require no treatment but can be considered as a pre-cancerous state. Monoclonal gammopathy of undetermined significance is quite frequent, and related to age. The risk of progression to multiple myeloma or another type of malignant lymphoproliferation is estimated at 1% per year. Monoclonal gammopathy of undetermined significance is twice as frequent in patients of African descent, and prevalence is higher for men. Diagnosis of MGUS is made on evidence of a monoclonal component < 30 g/L and no CRAB criteria (hypercalcaemia, renal insufficiency, anaemia, bone lesions). Regular monitoring is required for all MGUS because they can develop into other lymphoproliferative disorders such as multiple myeloma and lymphoma and other haematologic malignancies. In view of the genetic, insular and environmental context specificities of Caribbean populations of African descent, and according to haemophilia trends of the French West Indies cancer registry, it will be interesting to determine incidence and prevalence of MGUS in a country in the Caribbean. No such study has been performed to date. There is a hypothesis for a possible geographic distribution of these blood disorders linked to environmental exposure to pesticides. The expected findings and their potential repercussions will have major public health interest, and should form the basis for a wider prognostic study to determine risk factors for MGUS in the French Caribbean. In a real life exhaustive study, the Martinique Cancer Registry proposes an epidemiological focus on MGUS in Martinique.